Καναδάς - Αγγλικά - Health Canada

huntington laboratories canada ltd. - polyethoxy polypropoxy polyethoxy ethanol - iodine complex; nonyl phenoxypoly ethoxy ethanol-iodine - liquid - 11.3%; 10.8% - polyethoxy polypropoxy polyethoxy ethanol - iodine complex 11.3%; nonyl phenoxypoly ethoxy ethanol-iodine 10.8% - disinfectants (for agents used on object)

Καναδάς - Αγγλικά - Health Canada

huntington laboratories canada ltd. - alcohol anhydrous - liquid - 70% - alcohol anhydrous 70% - miscellaneous local anti-infectives

Καναδάς - Αγγλικά - Health Canada

huntington laboratories canada ltd. - chlorhexidine gluconate; isopropyl alcohol - liquid - 2%; 4% - chlorhexidine gluconate 2%; isopropyl alcohol 4% - miscellaneous local anti-infectives

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - tetrabenazine tablets are indicated for the treatment of chorea associated with huntington's disease. tetrabenazine tablets are contraindicated in patients: •who are actively suicidal, or in patients with untreated or inadequately treated depression [see warnings and precautions (5.1)]. •with hepatic impairment [see use in specific populations (8.6), clinical pharmacology (12.3)]. •taking monoamine oxidase inhibitors (maois). tetrabenazine tablets should not be used in combination with an maoi, or within a minimum of 14 days of discontinuing therapy with an maoi. [see drug interactions (7.3)]. •taking reserpine . at least 20 days should elapse after stopping reserpine before starting tetrabenazine tablets [see drug interactions (7.2)]. • taking deutetrabenazine or valbenazine [see drug interactions (7.7)]. teratogenic effects: risk summary there are no adequate data on the developmental risk associated with the use of tetrabenazine in pregnant women. administration of tetrabenazi

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - tetrabenazine tablets are indicated for the treatment of chorea associated with huntington's disease. tetrabenazine is contraindicated in patients: - who are actively suicidal, or in patients with untreated or inadequately treated depression [see warnings and precautions (5.1)]. - with hepatic impairment [see use in specific populations (8.6), clinical pharmacology (12.3)]. - taking monoamine oxidase inhibitors (maois). tetrabenazine should not be used in combination with an maoi, or within a minimum of 14 days of discontinuing therapy with an maoi [see drug interactions (7.3)]. - taking reserpine. at least 20 days should elapse after stopping reserpine before starting tetrabenazine [see drug interactions (7.2)]. - taking deutetrabenazine or valbenazine [see drug interactions (7.7)]. risk summary there are no adequate data on the developmental risk associated with the use of tetrabenazine in pregnant women. administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in s

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lundbeck pharmaceuticals llc - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - xenazine is indicated for the treatment of chorea associated with huntington’s disease. xenazine is contraindicated in patients: - who are actively suicidal, or in patients with untreated or inadequately treated depression [see warnings and precautions (5.1)]. - with hepatic impairment [see use in specific populations (8.6), clinical pharmacology (12.3)]. - taking monoamine oxidase inhibitors (maois). xenazine should not be used in combination with an maoi, or within a minimum of 14 days of discontinuing therapy with an maoi [see drug interactions (7.3)]. - taking reserpine. at least 20 days should elapse after stopping reserpine before starting xenazine [see drug interactions (7.2)]. - taking deutetrabenazine or valbenazine [see drug interactions (7.7)]. risk summary there are no adequate data on the developmental risk associated with the use of xenazine in pregnant women. administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspri

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

oceanside pharmaceuticals - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - tetrabenazine tablets are indicated for the treatment of chorea associated with huntington's disease. tetrabenazine tablets are contraindicated in patients: risk summary there are no adequate data on the developmental risk associated with the use of tetrabenazine tablets in pregnant women. administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspring mortality. administration of a major human metabolite of tetrabenazine to rats during pregnancy or during pregnancy and lactation produced adverse effects on the developing fetus and offspring (increased mortality, decreased growth, and neurobehavioral and reproductive impairment). the adverse developmental effects of tetrabenazine and a major human metabolite of tetrabenazine in rats occurred at clinically relevant doses [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

teva neuroscience, inc. - deutetrabenazine (unii: p341g6w9nb) (deutetrabenazine - unii:p341g6w9nb) - deutetrabenazine 6 mg - austedo®  xr and austedo®  are indicated in adults for the treatment of: - chorea associated with huntington’s disease [see clinical studies (14.1)] - tardive dyskinesia [see clinical studies (14.2)] austedo xr and austedo are contraindicated in patients: - with huntington’s disease who are suicidal, or have untreated or inadequately treated depression [see warnings and precautions (5.1)] . - with hepatic impairment [see use in specific populations (8.6), clinical pharmacology (12.3)] . - taking reserpine. at least 20 days should elapse after stopping reserpine before starting austedo xr or austedo [see drug interactions (7.2 )] . - taking monoamine oxidase inhibitors (maois). austedo xr and austedo should not be used in combination with an maoi, or within 14 days of discontinuing therapy with an maoi [see drug interactions (7.3 )] . - taking tetrabenazine or valbenazine [see drug interactions (7.6)] . risk summary there are no adequate data on the developmental risk associated with the use of austedo xr or a

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

tagi pharma, inc. - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - tetrabenazine tablet is indicated for the treatment of chorea associated with huntington's disease. tetrabenazine tablet is contraindicated in patients: risk summary there are no adequate data on the development risk associated with the use of tetrabenazine tablet in pregnant women. administration of tetrabenazine tablets to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offsprings mortality. administration of major human metabolite of tetrabenazine to rats during pregnancy or during pregnancy and lactation produced adverse effects on developing fetus and offspring (increased mortality, decreased growth and neurobehavioral and reproductive impairment). the adverse development effects of tetrabenazine and a major human metabolite of tetrabenazine in rats occurred at clinically relevant doses [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 % and 15 to 20%,

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

avkare - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - tetrabenazine tablet is indicated for the treatment of chorea associated with huntington's disease. tetrabenazine tablet is contraindicated in patients: - who are actively suicidal, or in patients with untreated or inadequately treated depression [see warnings and precautions (5.2)]. - with hepatic impairment [see use in specific populations (8.6), clinical pharmacology (12.3)]. - taking monoamine oxidase inhibitors (maois). tetrabenazine tablet should not be used in combination with an maoi, or within a minimum of 14 days of discontinuing therapy with an maoi [see drug interactions (7.3)]. - taking reserpine. at least 20 days should elapse after stopping reserpine before starting tetrabenazine tablet [see drug interactions (7.2)]. pregnancy category c there are no adequate and well-controlled studies in pregnant women. tetrabenazine tablet should be us